Le Lézard
Classified in: Health
Subjects: PDT, TRI

ObvioHealth Launches Next-Generation Outcomes Capture and Assessment Platform Advancing Data Accuracy in Decentralized Clinical Trials


NEW YORK, Jan. 13, 2022 /PRNewswire/ -- ObvioHealth, a global Virtual Research Organization (VRO), today announces the launch of Augmented ePRO, a first-of-its-kind offer in tech-enabled clinical trial service that combines AI-assisted ePRO instruments with a centralized clinical rating platform to deliver more accurate, standardized study outcomes.

Designed to address the subjectivity and variability that are characteristic of ePRO (electronic patient reported outcomes), this multi-pronged tool enables clinical trial participants to record source data?photos, audio, or video?in real time and upload it using the ObvioHealth app. Once the media is uploaded to the platform, each outcome is assessed and scored by a clinician and/or expert rater. Throughout the process, the COACH (Clinical Oversight And Coordination Hub) virtual site team, provides virtual support to both participants and raters, ensuring quality control from start to finish.

By leveraging the ease of ePRO, along with a centralized workflow for optimized expert ratings, Augmented ePRO offers clear benefits for all DCT stakeholders:

While facilitating more accurate endpoints today, the platform also contains features that can contribute to the novel outcomes of tomorrow. The clinical notes, or annotation, feature within Augmented ePRO allows clinicians to detail why a rating was determined. These notes can serve over time to program automatic ratings.

"Both patients and expert clinical raters will benefit from this AI-assisted tech platform throughout the data collection and assessment processes," said Ivan Jarry, co-founder and CEO of ObvioHealth. "But, with an eye towards the future, the annotation feature is especially useful,  allowing clinicians to easily capture nuances in patient ratings that can be used to train AI algorithms and lead to even better clinical rating processes in the future."

For more information about Augmented ePRO, visit https://www.obviohealth.com/landingpage/augmented-epro.

About ObvioHealth

ObvioHealth is an end-to-end?Virtual Research Organization (VRO) that delivers better data to sponsors and an easier clinical trial experience for participants. The company developed and launched one of the first patient-centric apps downloadable on smartphones, enabling?people to participate in clinical trials from the comfort of their homes. In the 5 years since launch, the company has been awarded?over 40 studies from 28 blue chip clients, implemented in 28?countries, across 15 different therapeutic areas.

SOURCE ObvioHealth


These press releases may also interest you

at 09:38
The Wyatt Foundation and The Conceive Fertility Foundation announce today a joint partnership that will award $15,000 grants to five individuals/couples who need in vitro fertility (IVF) to build their families. Launching during National Infertility...

at 09:38
New platform and surgery center investment adds advanced facility capabilities to specialty care network, strengthening in-person treatment and attracting leading orthopedic surgeons and physiciansWith Theater launch, value-based MSK care visionary...

at 09:34
The below resolutions were passed at Medicover's annual general meeting (the "AGM") held today on 26 April 2024. Election of the board of directors and auditor The AGM resolved, in accordance with the proposal from the nomination committee, that the...

at 09:00
Dental Care Acworth is thrilled to utilize this remarkable innovation and offer patients unbiased, objective and standardized dental care that they know they can trust. The AI solutions Pearl delivers can assist dental...

at 09:00
Tolland Hill Family Dental is thrilled to announce the addition of Dr. Conway Ma to its esteemed team of dental professionals. Tolland Hill Family Dental offers a wide range of services, catering to patients of all ages. From a child's first dental...

at 09:00
Amgen today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1...



News published on and distributed by: